The Reagan-Udall Foundation for the FDA is convening an invitation-only roundtable conversation with industry stakeholders and patient representatives, to discuss challenges in rare disease drug development and seek ways to enhance the efficiency and agility of generating evidence for regulatory review of rare disease medicines. Following the session, the Foundation will make the roundtable topline learnings publicly available.
argenx, Bridge Bio and Jazz Pharmaceuticals provided funding for this meeting.